Alpha-Synuclein Staging and Spreading in DLB — Spatial Propagation Mapping

🧫 Experiment Protocol ValidationParkinson's DiseaseDLBcell_lineproposed

# Alpha-Synuclein Staging and Spreading in DLB — Spatial Propagation Mapping ## Background and Rationale Spatial propagation mapping study to define alpha-synuclein spreading patterns in dementia with Lewy bodies (DLB), testing whether cortical-first spreading distinguishes DLB from Parkinson's disease dementia (PDD) where spreading is brainstem-first. **Protocol**: Post-mortem brain mapping in 40 DLB cases and 40 PDD cases across 20 brain regions (Braak staging + cortical and limbic sampling). Methods: (1) Alpha-synuclein phospho-Ser129 immunohistochemistry with stereological quantification. (2) Seeding amplification assay (SAA/RT-QuIC) measuring alpha-synuclein seeding activity per region. (3) Cryo-EM of filaments from early-affected regions to characterize DLB vs. PDD strain differences. (4) Synaptic alpha-synuclein localization via super-resolution microscopy (STED). (5) Correlation with clinical records (onset of cognitive vs. motor symptoms, dream enactment behavior, visual hallucination timing). **Primary Outcome**: Regional seeding activity map distinguishing DLB from PDD spreading patterns. **Success Criteria**: Identification of >3 brain regions with significantly different seeding activity profiles between DLB and PDD (p<0.01), supporting distinct propagation routes. **Model System**: Human post-mortem tissue with clinical correlation. **Expected Timeline**: 24 months. **Estimated Cost**: $800K. This experiment directly tests predictions arising from the following hypotheses: - **Microbial Metabolite-Mediated α-Synuclein Disaggregation** - **Cross-Seeding Prevention Strategy** - **Enteric Nervous System Prion-Like Propagation Blockade** - **Gut Barrier Permeability-α-Synuclein Axis Modulation** - **Noradrenergic-Tau Propagation Blockade** ## Experimental Protocol **Phase 1: Cell Line Preparation and Alpha-Synuclein Introduction (Days 1-3)** • Maintain H4 human neuroglioma cells and differentiated SH-SY5Y neuroblastoma cells at 37°C, 5% CO2 • Seed cells in 96-well imaging plates at 5×10^4 cells/well for time-course analysis • Prepare recombinant alpha-synuclein preformed fibrils (PFFs) at 5 μg/mL concentration • Introduce fluorescently-labeled alpha-synuclein (Alexa Fluor 488) to donor cells via lipofection • Establish co-culture system with 1:1 ratio of donor (alpha-synuclein+) to recipient cells **Phase 2: Spatial Propagation Monitoring (Days 4-21)** • Perform live-cell confocal microscopy every 48 hours using 63x oil immersion objective • Track alpha-synuclein aggregation using ThioflavinS staining (1 μg/mL, 30 min incubation) • Measure cell-to-cell transfer using proximity ligation assay (PLA) for alpha-synuclein interactions • Quantify spreading distance using automated image analysis (minimum 200 cells per timepoint) • Apply sequential staging criteria based on Braak staging adapted for cell culture models **Phase 3: Molecular Validation and Staging Classification (Days 22-25)** • Fix cells at defined timepoints (6h, 24h, 72h, 7d, 14d, 21d) using 4% paraformaldehyde • Perform immunocytochemistry using phospho-alpha-synuclein (Ser129) primary antibody (1:1000) • Conduct Western blot analysis for alpha-synuclein oligomers and fibrils • Apply machine learning-based staging algorithm to classify propagation patterns • Validate results using transmission electron microscopy for fibril morphology ## Expected Outcomes 1. **Progressive Alpha-Synuclein Spreading**: Observe 15-25% increase in alpha-synuclein positive cells per 48-hour interval, reaching 60-80% coverage by day 21 2. **Staged Propagation Pattern**: Identify distinct staging phases with Stage I (0-72h) showing local seeding, Stage II (3-7d) demonstrating short-range spreading, and Stage III (7-21d) exhibiting long-range propagation 3. **Distance-Dependent Transfer**: Measure exponential decay in transfer efficiency with distance, showing 80% efficiency within 50μm, 40% at 100μm, and <10% beyond 200μm 4. **Phosphorylation Dynamics**: Detect 3-5 fold increase in phospho-alpha-synuclein (Ser129) levels in recipient cells within 24-48 hours of contact 5. **Temporal Aggregation Kinetics**: Observe sigmoidal aggregation curve with lag phase (0-48h), exponential growth phase (48-168h), and plateau phase (>168h) 6. **Morphological Validation**: Confirm presence of 8-12 nm diameter alpha-synuclein fibrils in recipient cells using electron microscopy by day 14 ## Success Criteria • **Statistical Significance**: Achieve p<0.01 for cell-to-cell transfer efficiency compared to control conditions using two-way ANOVA with Bonferroni correction • **Staging Validation**: Successfully classify ≥85% of observed propagation patterns into defined stages using automated scoring algorithm with inter-rater reliability κ>0.8 • **Quantitative Spreading**: Demonstrate measurable spatial gradient with correlation coefficient r>0.7 between distance and transfer probability • **Molecular Confirmation**: Achieve >3-fold enrichment of phospho-alpha-synuclein in recipient cells with Western blot band intensity analysis (n≥6 biological replicates) • **Temporal Reproducibility**: Maintain <15% coefficient of variation in propagation kinetics across independent experimental runs (minimum n=4) • **Model Validation**: Confirm fibril morphology matches in vivo DLB characteristics with >90% agreement between electron microscopy observers

Source: wiki

🧫 Experiment Extras

🟢 Parkinson's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found